Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAT2506 versus Simponi in active psoriatic arthritis
2020-002004-39Phase 3Completed
- Sponsor
- Bio-Thera Solutions, Ltd.
- Start
- Dec 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of golimumab in psoriatic arthritis (PsA) (2 arms), sponsored by Bio-Thera Solutions, Ltd. Primary endpoint: ACR20 response at Week 8. Started Dec 2020; status: completed.
02
Drugs
golimumab
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on 2020-002004-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-002004-39.